These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1292120)

  • 21. [Familial hypercholesterolemia and plasma Lp(a) levels: 2 cardiovascular risk factors].
    Real JT; Romero G; Priego MA; Chaves FJ; Ascaso JF; Carmena R
    An Med Interna; 1999 Feb; 16(2):69-72. PubMed ID: 10192997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma Lp(a) values in familial hypercholesterolemia and its relation to coronary heart disease.
    Real JT; Ascaso JF; Chaves FJ; Tenés S; Priego MA; Puig O; Armengod ME; Carmena R
    Nutr Metab Cardiovasc Dis; 1999 Feb; 9(1):41-4. PubMed ID: 10726108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholesterol and lipoprotein(a) as risk factors for coronary heart disease in elderly subjects.
    Stober C; Clarke A; Mulvaney A; Harland J; Neithercut WD
    Br J Biomed Sci; 1994 Jun; 51(2):114-8. PubMed ID: 8049607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CETP (cholesteryl ester transfer protein) promoter -1337 C>T polymorphism protects against coronary atherosclerosis in Japanese patients with heterozygous familial hypercholesterolaemia.
    Takata M; Inazu A; Katsuda S; Miwa K; Kawashiri MA; Nohara A; Higashikata T; Kobayashi J; Mabuchi H; Yamagishi M
    Clin Sci (Lond); 2006 Nov; 111(5):325-31. PubMed ID: 16822236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The role of atherosclerosis risk factors in development of ischemic heart disease in young men].
    Ezhov MV; Afanas'eva OI; Kambegova AA; Afanas'eva MI; Trukhacheva EP; Naumov VG; Pokrovskiĭ SN
    Ter Arkh; 2009; 81(5):50-4. PubMed ID: 19537587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipoprotein(a), Friedewald formula, and NCEP guidelines. National Cholesterol Education Program.
    Scanu AM
    Am J Cardiol; 2001 Mar; 87(5):608-9, A9. PubMed ID: 11230848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [LDL cholesterol--why lower and lower?].
    Müller-Wieland D; Kotzka J
    MMW Fortschr Med; 2007 May; 149(22):28-30. PubMed ID: 18069223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is lipoprotein (a)-apheresis useful?
    Bambauer R
    Ther Apher Dial; 2005 Apr; 9(2):142-7. PubMed ID: 15828926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Lipoprotein(a) as a biochemical marker of coronary atherosclerosis].
    Ezhov MV; Afanas'ev OI; Benevolenskaia GF; Savchenko AP; Liakishev AA; Pokrovskiĭ SN
    Ter Arkh; 1997; 69(9):31-4. PubMed ID: 9411822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Lipoprotein(a) [Lp(a)]--a genetically related risk factor for arteriosclerosis].
    Feussner G; Feussner V; Ziegler R
    Med Klin (Munich); 1994 Apr; 89(4):198-203. PubMed ID: 8015535
    [No Abstract]   [Full Text] [Related]  

  • 31. [Lipoprotein(a): Aspects of pathophysiology, epidemiology and treatment].
    Thomas HP; Steinhagen-Thiessen E
    Z Kardiol; 2003; 92(Suppl 3):III53-8. PubMed ID: 14663603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The optimal low-density lipoprotein is 50 to 70 mg/dl.
    Clendenning R
    J Am Coll Cardiol; 2005 May; 45(10):1732; author reply 1732. PubMed ID: 15893199
    [No Abstract]   [Full Text] [Related]  

  • 33. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia.
    Miltiadous G; Saougos V; Cariolou M; Elisaf MS
    Ann Clin Lab Sci; 2006; 36(3):353-5. PubMed ID: 16951279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group.
    Kitabatake A; Sato H; Hori M; Kamada T; Kubori S; Hoki N; Minamino T; Yamada M; Kato T
    Clin Ther; 1994; 16(3):416-28. PubMed ID: 7923308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New aspects in lipidology and atherosclerosis.
    Superko HR
    Can J Cardiol; 1995 May; 11 Suppl C():4C-8C. PubMed ID: 7750049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum lipoprotein(a) levels in a Greek population sample without a history of premature myocardial infarction.
    Dionyssiou-Asteriou A; Rizos I
    J Cardiovasc Risk; 1996 Jun; 3(3):277-80. PubMed ID: 8863099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [An apheresis method in treatment of familial hypercholesterolemia].
    Derfler K
    Wien Klin Wochenschr; 2000 Jan; 112(2):49-51. PubMed ID: 10703150
    [No Abstract]   [Full Text] [Related]  

  • 38. [Extracorporeal plasma therapy in disorders of lipid metabolism: report of experiences with the H.E.L.P. system].
    Seidel D; Thiery J
    Internist (Berl); 1992 Jan; 33(1):54-61. PubMed ID: 1532384
    [No Abstract]   [Full Text] [Related]  

  • 39. Lipoprotein(a) may have contrasting effects on different aspects of atherosclerotic coronary disease.
    Narang R; Niththyananthan S; Nonis C; Thompson GR; Davies G
    Circulation; 1995 Oct; 92(8):2354-5. PubMed ID: 7554223
    [No Abstract]   [Full Text] [Related]  

  • 40. Multiple Methods for Reduction of Lipoprotein(a).
    Dalessandri KM
    Atherosclerosis; 2002 Aug; 163(2):409-10. PubMed ID: 12052489
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.